Arcutis Biotherapeutics Inc (NASDAQ: ARQT) kicked off on Friday, down -0.12% from the previous trading day, before settling in for the closing price of $8.50. Over the past 52 weeks, ARQT has traded in a range of $1.76-$13.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 303.42% over the last five years. While this was happening, its average annual earnings per share was recorded 60.14%. With a float of $101.14 million, this company’s outstanding shares have now reached $116.89 million.
The firm has a total of 296 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.17%, operating margin of -136.13%, and the pretax margin is -147.95%.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 13.42%, while institutional ownership is 99.65%. The most recent insider transaction that took place on Aug 02 ’24, was worth 47,064. In this transaction an insider of this company sold 5,220 shares at a rate of $9.02, taking the stock ownership to the 183,288 shares. Before that another transaction happened on Aug 02 ’24, when Company’s insider sold 13,206 for $9.02, making the entire transaction worth $119,106. This insider now owns 196,587 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.73 earnings per share (EPS), higher than consensus estimate (set at -0.86) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 60.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Take a look at Arcutis Biotherapeutics Inc’s (ARQT) current performance indicators. Last quarter, stock had a quick ratio of 8.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.13 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 3.36 million was lower than the volume posted last year of 3.73 million. As of the previous 9 days, the stock’s Stochastic%D was 39.04%. Additionally, its Average True Range was 0.76.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 24.27%, which indicates a significant increase from 22.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 74.96% in the past 14 days, which was lower than the 75.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.34, while its 200-day Moving Average is $7.26. Now, the first resistance to watch is $8.66. This is followed by the second major resistance level at $8.83. The third major resistance level sits at $9.07. If the price goes on to break the first support level at $8.24, it is likely to go to the next support level at $8.00. Now, if the price goes above the second support level, the third support stands at $7.83.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
The company with the Market Capitalisation of 992.40 million has total of 115,764K Shares Outstanding. Its annual sales at the moment are 59,610 K in contrast with the sum of -262,140 K annual income. Company’s last quarter sales were recorded 49,570 K and last quarter income was -35,380 K.
